Key Highlights

  • Amgen (NASDAQ:AMGN) is due after the close on November 3, 2026 with a calendar Market Value near USD 254.44 billion and consensus adjusted EPS of USD 5.79, below the USD 6.29 non-GAAP EPS of the second quarter, so the basis is unverified.
  • Pfizer (NYSE:PFE) is due before the open with a market value near USD 173.26 billion, calendar adjusted EPS of USD 0.73 and 2026 Revenue guidance of USD 60.5 billion to USD 62.5 billion, with COVID revenue near USD 4 billion.
  • Eaton (NYSE:ETN), valued near USD 146 billion, guides third quarter adjusted EPS to USD 3.46 to USD 3.56 against a USD 3.55 consensus, after Americas electrical orders rose 41 percent on a rolling basis.
  • Marathon Petroleum (NYSE:MPC), valued near USD 128.33 billion, faces calendar consensus EPS of USD 26. That compares with USD 17.73 of second quarter diluted EPS, a figure the calendar basis may not match.

Amgen (NASDAQ:AMGN): A Business in Transition

Amgen (NASDAQ:AMGN) is the largest of the four. Second quarter revenue was USD 10.1 billion, up 10 percent, with full-year guidance of USD 38.2 billion to USD 39.4 billion in revenue and USD 22.30 to USD 23.50 of non-GAAP EPS, unchanged in the second quarter release. Repatha rose 37 percent to USD 953 million, Evenity rose 38 percent to USD 714 million and Tezspire rose 42 percent, while Prolia fell 32 percent to USD 759 million as Volume fell 20 percent and net price fell 12 percent on biosimilars. Enbrel net selling price fell 22 percent after Medicare Part D price setting took effect on January 1, 2026. Free Cash Flow was USD 3.5 billion with no buybacks. MariTide has multiple Phase 3 studies ongoing, and higher spending on it contributed to R&D growth. Regulatory items include a request from the FDA to voluntarily withdraw Tavneos and a partial clinical hold on two blinatumomab studies. A 5 percent move would shift market value by about USD 12.7 billion, simple arithmetic and not options-implied. No peer result was verified.

Pfizer (NYSE:PFE): Growth Products Against COVID Decline

Pfizer (NYSE:PFE) reports before the open on Tuesday, November 3, 2026. One published estimate puts revenue near USD 15.91 billion, but its source is unidentified, so it is unverified. Second quarter revenue was USD 15.0 billion against a consensus of USD 14.388 billion, and adjusted EPS guidance of USD 2.80 to USD 3.00 absorbs an in-process R&D charge of about USD 0.10 per share. Comirnaty and Paxlovid fell 59 percent and 63 percent in the first quarter, while launched and acquired products generated USD 3.2 billion, up 18 percent. Guidance includes about USD 1.5 billion of pressure from generic and biosimilar competition, and the company has cited USD 9.7 billion of total cost savings through 2029. Vyndamax settlements extend effective U.S. protection to June 1, 2031. A bull case is revenue near USD 16 billion with a guidance raise. A bear case is weak Paxlovid demand. A 5 percent move is about USD 8.7 billion, simple arithmetic.

Eaton (NYSE:ETN): Backlog Strength, Consensus Near the Top

Eaton (NYSE:ETN) reports before the open on November 3, 2026. Consensus of USD 3.55 sits one cent below the top of third quarter guidance, and full-year adjusted EPS is guided to USD 13.40 to USD 13.60. Second quarter sales were a record USD 8.5 billion, up 21 percent, and shares rose about 7.3 percent after that report. Rolling orders rose 41 percent in Electrical Americas and 33 percent in Electrical Global, and segment Margin was down 80 basis points year over year in the second quarter. Electrical backlog rose 43 percent, Aerospace backlog rose 28 percent, and the guided segment margin of 24.6 percent to 25.0 percent compares with 23.1 percent in the second quarter. Acquisitions added 7 points to second quarter growth, so mix can shape reported sales. Vertiv (NYSE:VRT) reported on October 28, 2026 with revenue of USD 4.31 billion against USD 3.77 billion expected, and shares rose 15.2 percent, a strong read for Data Center power but a high benchmark. A 7 percent move would shift market value by about USD 10.2 billion, simple arithmetic.

Marathon Petroleum (NYSE:MPC): Peers Show Wide Margins

Marathon Petroleum (NYSE:MPC) reports before the open on November 3, 2026. The USD 26 calendar figure is about 47 percent above the second quarter, simple arithmetic, though consensus is typically adjusted and the figure is unverified. Valero Energy (NYSE:VLO) posted a USD 39.24 per barrel refining margin on October 23, 2026 and shares fell 3.98 percent that day, while Phillips 66 reported a USD 38.00 realized margin on October 28 with its share reaction not verified. Second quarter Net Income attributable to the company was USD 5.138 billion, and cash was USD 7.768 billion including USD 1.0 billion held at MPLX. Marathon's second quarter refining and Marketing margin was USD 36.33 per barrel, utilization was 94 percent, and it returned more than USD 2.8 billion. Shares outstanding fell to 283 million from 293 million, and USD 6.1 billion of repurchase authorization remained at June 30. A bear case is outages or margins normalizing. A 6 percent move would shift market value by about USD 7.7 billion, simple arithmetic.

Where Things Stand

The largest swing in dollar terms sits with Amgen (NASDAQ:AMGN), where a 5 percent move is about USD 12.7 billion, though its consensus basis is unverified. Pfizer (NYSE:PFE) will be judged on guidance and COVID decline more than on quarterly EPS. Eaton (NYSE:ETN) has the tightest bar, with consensus near the top of guidance after a strong peer. Marathon Petroleum (NYSE:MPC) has the biggest percentage gap to last quarter on a calendar figure that is unverified. These are previews, not forecasts, and market values are calendar figures.